# Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging

> **NCT00709852** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 402 (actual)

## Conditions studied

- Diagnostic Imaging
- Central Nervous System Diseases

## Interventions

- **DRUG:** Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- **DRUG:** Gadoteridol (ProHance)

## Key facts

- **NCT ID:** NCT00709852
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2014-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00709852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00709852, "Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00709852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*